Celltrion Launches Liquid Remsima IV in Europe to Lead Infliximab Market Celltrion has introduced the new liquid formulation of Remsima IV in Europe, aiming to bolster its global leadership in the infliximab therapeutic market and meet healthcare provider needs more effectively. The announcement represents a significant step in the company&r.. Read the news Thursday, 12 Mar 2026
Vertex’s Povetacicept Shows Breakthrough in Treating Kidney Diseases Vertex Pharmaceuticals announced that its experimental kidney disease drug povetacicept reached an important goal in a late-stage clinical trial, greatly increasing hopes for a successful treatment for immunoglobulin A nephropathy (IgAN). The positive data comes from a .. Read the news Wednesday, 11 Mar 2026
Angelini Pharma and Quiver Partner to Advance Genetic Epilepsies Angelini Pharma and Quiver Bioscience have announced a strategic research collaboration and licensing agreement. The collaboration aimed at accelerating the discovery of new therapies for genetic epilepsies. Under the multi-year agreement, Angelini Pharma will receive e.. Read the news Wednesday, 25 Feb 2026
What Is Human Serum Albumin and How It Drives Modern Medicine Human serum albumin is a remarkable protein that stands at the crossroads of biology, diagnostics, and therapeutic innovation. It is more than just a blood protein; it is a dynamic molecule influencing fluid balance, drug delivery, cell growth, and vaccine stability. It.. Read the news Wednesday, 25 Feb 2026
Pfizer to Acquire Metsera with Next-Generation Obesity Portfolio Pfizer Inc. will acquire Metsera Inc., adding a next-generation obesity portfolio to strengthen its obesity treatment pipeline and cardiometabolic expertise. Both boards approved the deal, aiming to position Pfizer as a leader in the highly competitive obesity therapeut.. Read the news Tuesday, 24 Feb 2026
FDA Approves BYSANTI™ (milsaperidone) for Bipolar I and Schizophrenia Vanda Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration approved BYSANTI™ (milsaperidone) as a new treatment option for adults diagnosed with bipolar I disorder and schizophrenia. This marks a significant leap forward in psychiatric medicin.. Read the news Monday, 23 Feb 2026
Alkermes Completes Avadel Deal, Expands Sleep Medicine Market Reach Alkermes plc has completed its acquisition of Avadel Pharmaceuticals plc, marking a decisive expansion into the competitive sleep medicine market. The company finalized the transaction, following approval by the High Court of Ireland under a scheme of arrangement. As a .. Read the news Friday, 13 Feb 2026
Bird Flu Virus: Risks, Symptoms, and Vaccines to Stay Safe The bird flu virus has emerged as a global health concern because of its ability to infect birds, spread widely, and occasionally affect humans. This highly pathogenic avian influenza, especially the H5N1 subtype, circulates in wild birds and poultry and can spill over .. Read the news Friday, 13 Feb 2026
Takeda’s $1.7B AI Drug Discovery Deal with Iambic Signals Shift Takeda Pharmaceutical Co. has signed a multi-year agreement worth more than $1.7 billion with U.S. biotech firm Iambic. The partnership aims to accelerate AI-driven drug discovery for small-molecule therapies targeting cancer and gastrointestinal diseases. This move sho.. Read the news Tuesday, 10 Feb 2026
Autoimmune Diseases: Prevalence, Diagnosis, and Treatment Advances Autoimmune diseases affect millions worldwide and continue growing in prevalence, complexity, and healthcare significance across modern medical systems. These conditions develop when the immune system mistakenly attacks healthy tissues, causing chronic inflammation, org.. Read the news Tuesday, 10 Feb 2026
